27,810 Shares in Humana Inc. (NYSE:HUM) Bought by Kennondale Capital Management LLC

Kennondale Capital Management LLC purchased a new position in Humana Inc. (NYSE:HUM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 27,810 shares of the insurance provider’s stock, valued at approximately $7,056,000. Humana makes up about 5.7% of Kennondale Capital Management LLC’s portfolio, making the stock its 3rd biggest holding.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HUM. Pzena Investment Management LLC increased its holdings in Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. FMR LLC increased its holdings in Humana by 23.4% in the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Retirement Systems of Alabama increased its holdings in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after acquiring an additional 192,801 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Humana in the 3rd quarter worth $50,102,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Humana by 42.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider’s stock worth $124,053,000 after acquiring an additional 115,820 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 4.5 %

Shares of HUM opened at $264.39 on Tuesday. The firm has a market cap of $31.91 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The company’s 50-day moving average price is $271.39 and its 200 day moving average price is $278.89. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays lifted their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $285.68.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.